The Weekly Recap 4/25/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure $164M in new funding, receive regulatory clearances, achieve clinical milestones, and much more on the road to LSI Asia ’25 in Singapore (June 10–13).

AMT Medical

Raised $25 million in Series B funding to accelerate the development of the ELANA® Heart Bypass System, a sutureless, minimally invasive alternative to open-heart coronary artery bypass surgery. The company aims to reduce complications, enable robotic compatibility, and cut procedure costs by over 50% with a standardized, beating-heart approach that eliminates the need for sternotomy or heart-lung machines.

Axoft

Completed the first four cases in its first-in-human clinical study of the Fleuron™ implantable brain-computer interface (iBCI), demonstrating safe implantation and high-resolution neural recordings. The ultrasoft iBCI captured stable single-neuron activity and a biomarker of consciousness, validating Axoft’s novel material for next-generation neurotech.

BackStop Neural

Appointed Dr. Kasra Amirdelfan to its Technical Advisory Board, adding deep clinical expertise in spinal cord stimulation (SCS) and pain management. His guidance will support BackStop Neural’s development of next-generation thin-film SCS leads aimed at expanding access and improving patient safety.

Biolinq

Closed a $100M Series C financing round to advance regulatory and commercial readiness for its intradermal glucose sensor. Biolinq’s biowearable platform combines continuous glucose monitoring with real-time metabolic insights, targeting people living with Type 2 diabetes not on insulin.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-42525-lsi-alumni-achievements-driving-medtech-and-healthtech-forward 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more